- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Direct Xa Inhibitor.
Displaying page 1 of 1.
EudraCT Number: 2021-004138-12 | Sponsor Protocol Number: TAK-330-3001 | Start Date*: 2022-10-25 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial with Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of TAK-330 for the Reversal of Dire... | |||||||||||||
Medical condition: Patients on treatment with Factor Xa Inhibitor needing for an urgent intervention associated with a high risk of bleeding. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000740-21 | Sponsor Protocol Number: LEX-210 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor. | |||||||||||||
Medical condition: Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) ES (Ongoing) AT (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002620-17 | Sponsor Protocol Number: 18-513 | Start Date*: 2019-01-08 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc | |||||||||||||
Full Title: A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR | |||||||||||||
Medical condition: Oral FXa inhibitor-treated patients with acute intracranial bleeding. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) NL (Completed) ES (Prematurely Ended) GR (Completed) CZ (Completed) LV (Completed) FI (Prematurely Ended) NO (Prematurely Ended) LT (Prematurely Ended) PL (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002138-35 | Sponsor Protocol Number: MEDEA | Start Date*: 2019-11-12 | ||||||||||||||||
Sponsor Name:Amsterdam University Medical Centers - location AMC | ||||||||||||||||||
Full Title: Heavy menstrual bleeding in premenopausal women treated with direct oral anticoagulants - the MEDEA study | ||||||||||||||||||
Medical condition: Heavy menstrual bleeding associated with direct oral anticoagulants in premenopausal women. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001785-26 | Sponsor Protocol Number: 14-505 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc. | |||||||||||||
Full Title: Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4). | |||||||||||||
Medical condition: Uncontrolled bleeding in patients who have taken either a direct factor Xa inhibitor (novel oral anticoagulants) or an indirect factor Xa inhibitor (low molecular weight heparins). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (Completed) BE (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004494-96 | Sponsor Protocol Number: BAY 59-7939/IMP 11899 | Start Date*: 2007-03-19 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary emb... | ||
Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) ES (Completed) SE (Completed) DE (Completed) FI (Completed) FR (Completed) HU (Completed) AT (Completed) IT (Completed) DK (Completed) CZ (Completed) NL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002263-96 | Sponsor Protocol Number: 39486 | Start Date*: 2012-07-11 |
Sponsor Name:MUMC | ||
Full Title: dabigatran and rivaroxaban: prediction of anticoagulant effect | ||
Medical condition: non valvular atrial fibrillation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001388-71 | Sponsor Protocol Number: CV185-017 | Start Date*: 2005-11-30 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic ... | ||
Medical condition: Acute Symptomatic Deep Vein Thrombosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) AT (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002442-45 | Sponsor Protocol Number: AXAFA-AFNET5 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)] | ||||||||||||||||||||||||||||
Full Title: Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy. | ||||||||||||||||||||||||||||
Medical condition: Atrial fibrillation catheter ablation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) AT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002171-16 | Sponsor Protocol Number: BAY 59-7939 / 11528 | Start Date*: 2005-01-10 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. | |||||||||||||
Medical condition: Acute syntomatic deep vein thrombosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003303-31 | Sponsor Protocol Number: BAY59-7939/13238 | Start Date*: 2009-01-13 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: The Einstein CYP cohort study. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism using a strong CYP 3A4 inducer. | ||
Medical condition: Patients with acute, proximal DVT or acute PE who concomitantly use a strong CYP 3A4 inducer for the entire 3-month study duration. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) HU (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-002457-41 | Sponsor Protocol Number: 150-CL-008 | Start Date*: 2006-05-15 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open... | |||||||||||||
Medical condition: Elective primary hip replacement surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Completed) SE (Completed) NO (Completed) FI (Completed) PT (Completed) GR (Completed) IT (Completed) LT (Completed) EE (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004495-13 | Sponsor Protocol Number: BAY 59-7939/11702 | Start Date*: 2007-03-12 |
Sponsor Name:Bayer Healthcare AG | ||
Full Title: Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. | ||
Medical condition: Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) ES (Completed) SE (Completed) FR (Completed) DE (Completed) FI (Completed) DK (Completed) HU (Completed) AT (Completed) IT (Completed) GB (Completed) CZ (Completed) NL (Completed) IE (Completed) LT (Completed) EE (Completed) LV (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000112-33 | Sponsor Protocol Number: NL47761.041.14 | Start Date*: 2014-09-01 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation. A randomised phase II clinical trial. | ||
Medical condition: The prevention of ischaemic stroke in patients with atrial fibrillation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000353-26 | Sponsor Protocol Number: SAFE-SSPE | Start Date*: 2021-09-20 |
Sponsor Name:Bern University Hospital | ||
Full Title: Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Placebo-Controlled Non-Inferiority Trial | ||
Medical condition: Isolated subsegmental pulmonary embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001083-43 | Sponsor Protocol Number: BAY 59-7939 / 11223 | Start Date*: 2004-11-23 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis ODIXa-DVT A prospective, randomized, multinational, multicenter, partially blinded, parallel-grou... | |||||||||||||
Medical condition: Acute deep vein thrombosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001094-58 | Sponsor Protocol Number: BAY 59-7939 / 15572 | Start Date*: 2011-09-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Prospective, multi-center, randomized, heparin-controlled dose-finding trial to evaluate the efficacy and safety of rivaroxaban, a direct factor Xa inhibitor, on the background of standard dual ant... | |||||||||||||
Medical condition: Symptomatic CAD patients due to undergo an elective (non emergent) Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary vessel(s). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000485-34 | Sponsor Protocol Number: 105SAR301 | Start Date*: 2017-10-16 | |||||||||||
Sponsor Name:TRACON Pharmaceuticals, Inc. | |||||||||||||
Full Title: A randomized Phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS) | |||||||||||||
Medical condition: Advanced angiosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) FR (Completed) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.